Skip to content
SitemapMIA Media2021-09-10T15:30:19+10:00
Pages
Posts by category
- Category: Forums
- Category: Treatment
- Category: Research Life
- Category: Observership
- Category: Volunteering
- Category: Awareness
- Category: Careers
- Category: Education
- Category: Events
- Category: Fundraising
- Category: Partners
- Category: Patient Support
- Category: People
- Category: Research News
- Category: Research Projects
- Category: Uncategorized
Papers
- Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
- Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
- Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study.
- Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations.
- A multimodal vision foundation model for clinical dermatology.
- Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders.
- Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update.
- Predicting Sentinel Node Positivity in Melanoma Patients: Personalized Tools Outperform National Comprehensive Cancer Network and American Joint Committee on Cancer Based Criteria.
- Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.
- A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis.
- Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial.
- Diagnostic Potential of 68Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease.
- ASO Visual Abstract: Cartilage Resection in the Surgical Management of Ear Melanoma.
- Do BRAF-targeted therapies have a role in the era of immunotherapy?
- Reflectance confocal microscopy terminology for nonmelanocytic skin lesions: A Delphi consensus of experts.
- Federated deep learning enables cancer subtyping by proteomics.
- The Value of Sentinel Node Biopsy in Patients With Higher-Risk (T3, T4) Primary Cutaneous Melanomas: Insights Provided by a Stage II Risk Calculator.
- Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.
- Cartilage Resection in the Surgical Management of Ear Melanoma.
- Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial.
- Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort.
- Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma.
- Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.
- Molecular Analysis of Cutaneous Sarcomatoid Neoplasms Frequently Identifies Melanoma Driver Variants.
- Shifts in Cutaneous Melanocytic Tumor Diagnostic Terminology: Melanocytoma, MPATH-Dx V2.0 and the WHO Skin5.
- Management of Local Skin Reactions Caused by 5-FU 4% Cream for the Treatment of Actinic Keratosis: A Delphi Consensus.
- Reconsidering the surgical approach in cutaneous melanoma: does wide local excision after a complete diagnostic excision reduce the risk of recurrence?
- External validation of a model to predict recurrence-free and melanoma-specific survival for patients with melanoma after sentinel node biopsy.
- Absolute Risk of Developing a Second Primary Cancer After a First Primary Melanoma: An Australian Population-Based Cohort Study.
- Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040
- Circulating MicroRNAs: functional biomarkers for melanoma prognosis and treatment.
- Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma.
- ASO Author Reflections: A Cost-Effectiveness Decision About Groin Lymphadenectomy: Reflections from the EAGLE FM Randomized Trial.
- Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study.
- Reduction in surgical interventions in melanoma.
- Transforming Clinical Trials in Skin Cancer Research: Exploring the Potential of Flexible and Innovative Designs.
- Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors.
- Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
- Association of inherited genetic variants with multiple primary melanoma.
- Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K mutated melanoma (EBIN): an international randomized phase II study.
- Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study.
- FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma.
- Single-Cell Multi-Omics: Insights into Therapeutic Innovations to Advance Treatment in Cancer.
- Incarcerated lateral inguinal hernia following ilioinguinal lymph node dissection: an unusual case.
- Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.
- Use of Patient Reported Outcome Measures (PROMs) in Clinical Care: A Community-Based Allied Health Setting.
- In vivo reflectance confocal microscopy role for early to advanced lentigo maligna melanoma spectrum: A systematic review and pooled analysis.
- Economic Evaluation of Inguinal Versus Ilio-inguinal Lymphadenectomy for Patients with Stage III Metastatic Melanoma to Groin Lymph Nodes: Evidence from the EAGLE FM Randomized Trial.
- Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.
- Sociodemographic and health factors associated with genetic testing in Australia: insights from a cohort-based study of 45,061 participants.
- Reflectance confocal microscopy: Presurgical margin assessment improves lentigo maligna and lentigo maligna melanoma management.
- Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma.
- G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma.
- A scoping review of factors influencing the implementation of liquid biopsy for cancer care.
- Health-related Quality of Life and hospital costs of Finnish melanoma patients participating in the second Multicenter Selective Lymphadenectomy Trial (MSLT-II).
- Strategies to promote the completion of patient-reported outcome measures by culturally and linguistically diverse and Indigenous Peoples in clinical care settings: A systematic review.
- Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
- Response to han and liu.
- Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.
- Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.
- Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial.
- Outcomes With Radiation Therapy as Primary Treatment for Unresectable Cutaneous Head and Neck Squamous Cell Carcinoma.
- Mohs micrographic surgery for the treatment of invasive melanoma: A systematic review with meta-analyses.
- Quality and usability of photographs of skin conditions taken in emergency departments for dermatology consultation.
- Experience, knowledge, practices and attitudes of emergency department medical staff regarding teledermatology.
- Approaches to Surgical Management of Anorectal Melanoma in the Pre- and Post-Immunotherapy Eras.
- The tumor immune microenvironment in primary cutaneous melanoma.
- European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024.
- Cancer cells impair monocyte-mediated T cell stimulation to evade immunity.
- Real-World Melanoma Miss-Rate In An NHS Hospital Dermatology Service. A Retrospective Study.
- The impact of surgical margins in managing regional metastases in cutaneous squamous cell carcinoma of the head and neck.
- Harnessing Molecular Insights for Translational Impact: Highlights from the Special Issue Titled "New Insights in Translational Bioinformatics".
- Letter to Editor: Avoiding statistical pitfalls when assessing the performance of risk prediction nomograms.
- Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.
- Sex differences in melanoma survival-a GEM study.
- Sentinel Node Biopsy in Melanoma Remains a Valuable Clinical Tool. Comment on Dixon et al. Primary Cutaneous Melanoma-Management in 2024. J. Clin. Med. 2024, 13, 1607.
- Approaches to Surgical Management of Anorectal Melanoma in the Pre- and Post-Immunotherapy Eras.
- Long-term survival across Breslow thickness categories: findings from a population-based study of 210 042 Australian melanoma patients.
- Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey.
- Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.
- X and Y Differences in Melanoma Survival Between the Sexes.
- An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma.
- ASO Author Reflections: Is Sentinel Node Biopsy Still of Value for Patients with High-Risk Primary Melanomas Eligible for Adjuvant Immunotherapy?
- Uncovering the molecular mechanisms of amelanotic/hypopigmented primary cutaneous melanoma
- Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: protocol for an online randomised study.
- Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
- Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.
- Acceptability and appropriateness of a risk-tailored organised melanoma screening program: Qualitative interviews with key informants.
- The Development and Evaluation of a Convolutional Neural Network for Cutaneous Melanoma Detection in Whole Slide Images.
- Risk of Death Due to Melanoma and Other Causes in Patients With Thin Cutaneous Melanomas.
- Incidental Disappearing Proficient Mis-Match Repair Colon Cancer in a Patient with Advanced Metastatic Melanoma and the Rare Complications of Immunotherapy.
- Clinical significance of intra-thoracic and intra-abdominal sentinel lymph nodes detected on lymphoscintigraphy in truncal melanoma patients.
- Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma.
- Update of clinical practice guidelines for the management of patients with sarcoma.
- Survival Outcomes in Patients Undergoing Pelvic Exenteration for Pelvic Mucosal Melanomas: Retrospective Single Institution Australian Study.
- Tissue-Based Profiling Techniques to Achieve Precision Medicine in Cancer: Opportunities and Challenges in Melanoma.
- Adjuvant systemic therapy in melanoma: Relative versus absolute benefit; the number needed to treat (NNT) versus the number needed to harm (NNH)?
- Short-Term Effectiveness of a Stepped-Care Model to Address Fear of Cancer Recurrence in Patients With Early-Stage Melanoma.
- Editorial Expression of Concern: Temozolomide induces senescence but not apoptosis in human melanoma cells.
- Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.
- Patient and Staff Experiences of Embedding Electronic Patient Reported Outcome Measures for Distress Screening and Quality of Life Assessment, Into Routine Melanoma Care: A Mixed-Methods Study.
- Nivolumab (NIVO) plus relatlimab (RELA) vs. NIVO in previously untreated, metastatic, or unresectable melanoma (RELATIVITY-047): 3- year overall survival (OS) and melanoma-specific survival (MSS) results.
- 121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: Final analysis from the randomized part 2 of the phase I/II CA027-002 study.
- Efficacy and safety of nivolumab + relatlimab (NIVO+RELA) versus nivolumab + ipilimuab (NIVO+IPI) in the first-line (1L) treatment of advanced melanoma: updated data from an indirect treatment comparison.
- Impact of an online risk prediction tool for sentinel node metastasis on clinical decision-making in melanoma care: A mixed methods study.
- Nivolumab vs. Placebo in the Adjuvant Treatment of Patients with Stage IIB/C Melanoma: 3-Year Results of the CheckMate 76K (CM 76K) Study.
- European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.
- The Impact of Preoperative Facial Nerve Weakness and Facial Nerve Outcomes in the Management of Patients With Parotid Metastases of Cutaneous Squamous Cell Carcinoma.
- Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
- Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo.
- Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.
- Long-term Outcomes among Patients Who Respond within the First Year to Nivolumab plus Ipilimumab or Nivolumab Monotherapy: A Pooled Analysis in 935 Patients.
- An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma.
- An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma.
- Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
- In vivo reflectance confocal microscopy role for early to advanced lentigo maligna melanoma spectrum: A systematic review and pooled analysis.
- A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases
- DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance.
- Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
- BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment.
- Outcomes for smokers who develop melanoma: a systematic review and meta-analysis.
- Effect of smoking on melanoma incidence: a systematic review with meta-analysis.
- Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.
- Impact of Clinical Information on Melanocytic Skin Lesion Pathology Diagnosis: A Scoping Review.
- Uptake of health economic evaluations alongside clinical trials in Australia: an observational study.
- Computer vision methods under rapid evolution for pathology image tasks
- Variation in initial biopsy technique for primary melanoma diagnosis: A population-based cohort study in New South Wales, Australia.
- Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response.
- Remote cutaneous confocal microscopy: A multicentric prospective study evaluating diagnostic accuracy for melanoma and keratinocyte carcinoma in tertiary settings.
- 7760 Identifying Conventional and Novel Biomarkers to Predict Checkpoint Inhibitor Associated Autoimmune Diabetes
- Evaluation of Multiple Tissue Levels Frequently Upstages Patients With Clinically Localized Thin Primary Cutaneous Melanoma.
- The Prognostic Significance of Tumoral Melanosis
- A brave new framework for glioma drug development.
- Two decades of advances in clinical oncology - lessons learned and future directions.
- Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
- 1090P High concurrent interferon gamma signature expression in the primary tumor and lymph node metastasis is associated with superior outcome upon neoadjuvant ipilimumab + nivolumab in stage III melanoma
- 1082O KEYMAKER-U02 substudy 02C: Neoadjuvant pembrolizumab (pembro) and investigational agents followed by adjuvant pembro for stage IIIB-D melanoma
- 1092P Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047
- 1094P NeoRisk: Neoadjuvant immunotherapy (NeoIT) recurrence risk assessment tool
- Neoadjuvant pembrolizumab plus lenvatinib in patients with resectable stage III melanoma (NeoPele): Analysis of tumor microenvironment (TME) correlated to pathological
- LBA41 Long-term survival with neoadjuvant therapy in melanoma: Updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- 1106P NivoLag-when: International real-world study of combination immunotherapy sequences in melanoma
- 1083P KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma
- 1943P Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort
- 72MO Concurrent BRAF targeted therapy (TT) with dabrafenib and trametinib and anti-PD-1 agent pembrolizumab (PD1) increased B cell signalling and inflammatory pathways more effectively than when given sequentially or with anti-PD-1 alone
- 1088P Molecular profiling and matched targeted therapy for patients with advanced melanoma: Results from part I of the MatchMEL study
- Regular whole blood donation and gastrointestinal, breast, colorectal and haematological cancer risk among blood donors in Australia
- Choroidal melanoma in a patient with multiple endocrine neoplasia type 1.
- Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
- Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
- Acceptability and timing considerations when administering patient-reported outcome measures (PROMs) among people with chronic health conditions who are culturally and linguistically diverse (CALD): a qualitative study protocol.
- Reply to: Pioneering combination: Nivolumab and isolated limb perfusion in melanoma in-transit metastases treatment.
- Towards evidence-based skin checks
- Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy.
- Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
- What is behind the declining incidence of melanoma in younger Australians?
- Criteria for assessing evidence for biomarker-targeted therapies in rare cancers-an extrapolation framework.
- Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
- 53808 Adjuvant Pembrolizumab Versus Placebo in Stage IIB or IIC Melanoma: Exploratory Post Hoc Analyses of Patients with New Primary Melanoma and Other Skin Cancers from the Phase 3 KEYNOTE-716 Study
- Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors.
- Melanoma medicine: New drugs for melanoma and the role of the general practitioner.
- The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort
- Weakly supervised deep learning image analysis can differentiate melanoma from naevi on haematoxylin and eosin-stained histopathology slides
- A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma.
- Mobile teledermoscopy for patients at high risk of cutaneous melanoma: A single-arm, feasibility study of a clinical intervention at two tertiary centres (MOBILEMEL)
- Adherence to melanoma screening and surveillance skin check schedules tailored to personal risk
- Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy.
- Targeted Screening for Cancer: Learnings and Applicability to Melanoma: A Scoping Review
- The SLICE-3D dataset: 400,000 skin lesion image crops extracted from 3D TBP for skin cancer detection.
- First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
- Response to Letter to the Editor from Hao and Xue: "Checkpoint Inhibitor-associated Autoimmune Diabetes Mellitus Is Characterized by C-Peptide Loss and Pancreatic Atrophy"
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
- Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238
- Treatment of melanoma brain metastases with radiation and immunotherapy or targeted therapy: A systematic review with meta-analysis
- The use of linked administrative data in Australian randomised controlled trials: A scoping review.
- Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module.
- Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.
- Synchronous collision metastasis of melanoma and squamous cell carcinoma in a parotid lymph node: a very rare occurrence and literature review
- Quality measures in primary care skin cancer management: a qualitative study of the views of key informants
- Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas
- Predicting sentinel node positivity in patients with primary cutaneous melanoma: an international multicentre study validating and refining the MIA risk calculator
- Case report: neuroendocrine tumour causing torsion of the appendix in an adolescent—a rare and unexpected twist
- Estimating the magnitude and healthcare costs of melanoma in situ and thin invasive melanoma overdiagnosis in Australia.
- Magnetic seed localization is feasible for non-palpable melanoma, Merkel cell carcinoma, and soft tissue sarcoma lesions
- Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy
- DP03 Melanoma detection in whole-slide images using a convolutional neural network for objective prognostic biomarker generation
- Public Preferences for Genetic and Genomic Risk-Informed Chronic Disease Screening and Early Detection: A Systematic Review of Discrete Choice Experiments
- Predictors of malignancy in melanocytic lesions presenting as new lesions compared to baseline total body photography: A case-control study.
- ASO Author Reflections: The Role of Postoperative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck: Now and into the Future
- Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.
- Exploiting temporal aspects of cancer immunotherapy
- Exploiting temporal aspects of cancer immunotherapy
- When does a melanoma metastasize? Implications for management
- Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
- Randomized Trial of Postoperative Radiation Therapy After Wide Excision of Neurotropic Melanoma of the Head and Neck (RTN2 Trial 01.09)
- Patient demographic characteristics and risk factors associated with sun protection behaviours in specialist melanoma clinics
- Mohs micrographic surgery for the treatment of invasive melanoma: A systematic review with meta-analyses
- Skin checks for potential skin cancers in general practice in Victoria, Australia: the upfront and downstream patterns and costs.
- Management of Localized Melanoma in the Anti-PD-1 Era
- Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
- Methods to Include Environmental Impacts in Health Economic Evaluations and Health Technology Assessments: A Scoping Review
- Regarding sentinel lymph node biopsy in younger and older patients.
- The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial).
- Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma
- Use of early circulating tumour DNA dynamics in patients with stage III melanoma receiving neoadjuvant combination immunotherapy.
- Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study.
- The evolution of melanomology: a tale of giants' shoulders and bold hypotheses
- Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas
- Quality of life outcomes in patients receiving dental implants in vascularised bone flaps for mandibular reconstruction.
- Association of optimism and social support with health-related quality of life among Australian women cancer survivors - A cohort study
- The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort
- Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115
- Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115
- Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma
- Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.
- Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.
- Perspectives of health professionals and patients on implementation of a predictive model of response to immunotherapies in advanced melanoma
- Abstract LBO1-03: Randomized Phase II Study of Neoadjuvant Nivolumab (N) 2 week lead-in followed by 12 weeks of concurrent N+carboplatin plus paclitaxel (CbP) vs concurrent N+CbP in Triple Negative Breast Cancer (TNBC): (BCT1902/IBCSG 61-20 Neo-N)
- Examining labelling guidelines for AI-based software as a medical device: A review and analysis of dermatology mobile applications in Australia
- Merkel-cell carcinoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.
- Merkel-cell carcinoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.
- Full-body skin examination in screening for cutaneous malignancy: a focus on concealed sites and the practices of Australian dermatologists.
- Neoadjuvant Triplet Immune Checkpoint Blockade in Newly Diagnosed Glioblastoma.
- Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.
- Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma
- An Approach to Evaluate the Costs and Outputs of Academic Biobanks
- Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis
- Single-Cell Informatics for Tumor Microenvironment and Immunotherapy.
- Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.
- Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses.
- The Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms
- Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma
- Cancer in general practice research priorities in Australia.
- Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
- Skin cancer referrals by nonmedical practitioners: a prospective observational study,
- Impact of whole brain radiotherapy after treatment of melanoma brain metastases on an individual’s employment and household income
- ASO Author Reflections: Lymphoedema Related to Inguinal and Ilioinguinal Lymphadenectomy for Melanoma.
- BRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms.
- Cancer in general practice research priorities in Australia.
- Neo-Adjuvant Therapy for Metastatic Melanoma.
- POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.
- POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis
- Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective, Randomised Trial.
- Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy.
- Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
- Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
- Technical considerations for isolated limb perfusion: A consensus paper.
- Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
- First Phase Development of a Patient-reported Outcome Measure for Midface Oncology
- Correction: Exploring the Integration of Environmental Impacts in the Cost Analysis of the Pilot MEL-SELF Trial of Patient-Led Melanoma Surveillance
- A gut microbial signature for combination immune checkpoint blockade across cancer types.
- Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
- International expert recommendations on image acquisition for in vivo reflectance confocal microscopy of cutaneous tumors.
- Prognostic and predictive biomarkers in head and neck cancer: something old, something new, something borrowed, something blue and a sixpence in your shoe.
- Transforming nursing assessment in acute hospitals: A cluster randomised controlled trial of an evidence-based nursing core assessment (the ENCORE trial).
- Transmission and Non-transmission of Melanoma From Deceased Solid Organ Donors to Transplant Recipients: Risks and Missed Opportunities.
- PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma.
- Minimum labelling requirements for dermatology artificial intelligence-based Software as Medical Device (SaMD): A consensus statement.
- Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.
- The difficulty with measuring the largest melanoma tumour diameter in sentinel lymph nodes.
- Implementation considerations for risk-tailored cancer screening in the population: A scoping review
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
- Commentary: Real-world post-deployment performance of a novel machine learning-based digital health technology for skin lesion assessment and suggestions for post-market surveillance
- A review of skin cancer primary prevention activities in primary care settings.
- Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.
- Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe.
- Smoking Status and Survival in Patients With Early-Stage Primary Cutaneous Melanoma.
- Pathology: the narrative continues.
- Synchronous collision metastasis of melanoma and squamous cell carcinoma in a parotid lymph node: a very rare occurrence and literature review.
- Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
- Cutaneous malignancies in chronic lymphocytic leukemia.
- Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.
- Rethinking the urgency priority system in round hole detachments, which should be done first? Macula on or macula off.
- Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
- Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
- CD4+ T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses.
- Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study.
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
- Associations between patient-level health literacy and diagnostic time intervals for head and neck cancer: A prospective cohort study.
- Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.
- SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma.
- Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node Status.
- Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
- Implementing systematic melanoma risk assessment and risk-tailored surveillance in a skin cancer focussed dermatology clinic: A qualitative study of feasibility and acceptability to patients and clinic staff.
- Prognostic significance of sentinel node tumor burden in Merkel Cell Carcinoma.
- Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy.
- Knowledge of sentinel lymph node status improves accuracy when predicting melanoma mortality and selecting patients for adjuvant immunotherapy.
- Long-term cost-effectiveness of a melanoma prevention program using genomic risk information compared with standard prevention advice in Australia
- The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.
- Prognostic and predictive biomarkers in melanoma.
- Insights into the statistical quality of randomized clinical trial reports submitted to the British Journal of Dermatology.
- Prognostic and predictive biomarkers in head and neck cancer: something old, something new, something borrowed, something blue and a sixpence in your shoe
- Gamification and serious games in dermatology education: A systematic review and quality assessment.
- Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
- Embedding stakeholder preferences in setting priorities for health research: Using a discrete choice experiment to develop a multi-criteria tool for evaluating research proposals.
- Ex vivo tissue modelling informs drug selection for rare cancers.
- ASO Author Reflections: Recurrence in Sentinel Node-Positive Node Fields in Melanoma Patients Undergoing Surveillance Is More Common outside the Node Field.
- In-depth profiling of tumor tissue derived from malignant pleural mesothelioma patients identifies potential biomarkers predicting response to immune-checkpoint inhibitor therapy
- Acceptability and appropriateness of a risk-tailored organised melanoma screening program: Qualitative interviews with key informants.
- Neoadjuvant relatlimab and nivolumab in resectable melanoma.
- Dermoscopy of Lentiginous Melanomas and Equivocal Benign Pigmented Macules of the Scalp: A Case-Control Multicentric Study.
- Full-body skin examination in screening for cutaneous malignancy: a focus on concealed sites and the practices of Australian dermatologists.
- Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma.
- Immune checkpoint inhibitor-induced lichenoid drug eruption-sparing scar burns.
- Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.
- A tailored approach to horizon scanning for cancer medicines.
- The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
- A review of skin cancer primary prevention activities in primary care settings.
- Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging.
- Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.
- Single-cell RNA sequencing in melanoma: what have we learned so far?
- Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma.
- Affecting change as a clinical academic.
- Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
- European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.
- Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
- VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types - A Meta-Analysis
- Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?
- Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
- Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
- Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET/CT–confirmed complete response
- Uncovering the complex relationship between balding, testosterone and skin cancers in men
- Comparison of humans versus mobile phone-powered artificial intelligence for the diagnosis and management of pigmented skin cancer in secondary care: a multicentre, prospective, diagnostic, clinical trial
- ACEMID cohort study: protocol of a prospective cohort study using 3D total body photography for melanoma imaging and diagnosis
- Position statement of the EADV Artificial Intelligence (AI) Task Force on AI-assisted smartphone apps and web-based services for skin disease.
- Long-Term Outcomes and Persistent Toxicities Following BRAF/MEK Inhibitor Therapy for Advanced Melanoma.
- Online tools for predicting melanoma survival: including sentinel node status as a variable improves prediction accuracy.
- Harold Gillies, pioneer of modern plastic surgery, and Donald Morton, pioneer of modern surgical oncology: master problem-solvers and surgical role models
- Prognosis for people with multiple primary melanomas compared with a single primary melanoma.
- COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma
- An adapter window for precise skin marking during handheld reflectance confocal microscopic scanning.
- An adapter window for precise skin marking during handheld reflectance confocal microscopic scanning.
- Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results
- Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
- Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma
- Checkpoint kinase 1 inhibitor + low-dose hydroxyurea efficiently kills BRAF inhibitor- and immune checkpoint inhibitor-resistant melanomas
- Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.
- The effect of age on melanoma incidence and prognosis
- Systemic Therapy for Melanoma: ASCO Guideline Update
- Risk factors for subsequent primary melanoma for patients with previous melanoma: A systematic review and meta-analysis
- Single cell profiling of tumour biopsies and heterogeneity in response of dedifferentiated melanoma
- Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma.
- Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
- Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose
- Does preoperative imaging for scalp non-melanocytic skin cancer accurately predict invasion of the cranial vault? A systematic review and meta-analysis.
- Fascio-cutaneous and fascio-periosteal free flaps for treatment of intermediate stage osteoradionecrosis of the jaws
- Supportive care needs in Australian melanoma patients and caregivers: results from a quantitative cross-sectional survey
- Unicentric Castleman's disease imitating metastatic melanoma: A case report
- Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st–3rd, 2022—Naples, Italy)
- European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.
- European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023
- Implementing structured pathology reporting protocol for non-melanocytic skin cancers: practical considerations.
- Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
- Implementing structured pathology reporting protocol for non-melanocytic skin cancers: practical considerations
- Unicentric Castleman's disease imitating metastatic melanoma: A case report.
- Association of functional, inherited vitamin D-binding protein variants with melanoma-specific death
- Looking beyond workforce parity: addressing gender inequity in pathology
- Looking beyond workforce parity: addressing gender inequity in pathology.
- Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
- Cutaneous melanoma: a contemporary overview.
- Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
- Acceptability of risk-tailored cancer screening among Australian GPs: a qualitative study.
- Acceptability of risk-tailored cancer screening among Australian general practitioners: a qualitative study
- Multiomics analysis reveals a Type III driven immune response in immunotherapy-induced toxicity in melanoma and identifies potential new therapeutic targets.
- Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma in Patients with Concomitant Chronic Lymphocytic Leukemia
- Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.
- Delphi Consensus Among International Experts on the Diagnosis, Management, and Surveillance for Lentigo Maligna
- Delphi Consensus Among International Experts on the Diagnosis, Management, and Surveillance for Lentigo Maligna.
- Vasopressors improve outcomes in autologous free tissue transfer: A systematic review and meta-analysis
- The association of dermatologist demographic density with melanoma survival in New South Wales, Australia.
- Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma-A Discrete Choice Experiment.
- Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
- Inter-rater concordance of basal cell carcinoma subtypes: influences on reporting format and opportunities for further classification modifications.
- Melanoma In Situ—Getting the Diagnosis and Prognosis Right.
- Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing
- Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy.
- One step closer to improving melanoma diagnosis and prognosis with liquid biopsies.
- Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer
- Author Correction: The landscape of viral associations in human cancers
- Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers
- Modeling Methods in Craniofacial Virtual Surgical Planning.
- Author Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition.
- Epidemiology, staging and management of mucosal melanoma of the head and neck: a narrative review.
- Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose.
- Epidemiology, staging and management of mucosal melanoma of the head and neck: a narrative review
- Abstract CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial
- Reply to: 'Melanoma diagnosis at a specialist dermatology practice without the use of photographic surveillance'.
- Risk Factors and Characteristics of Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes.
- ASO Visual Abstract: Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma
- Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma.
- Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
- Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.
- Sex-Specific Associations of MDM2 and MDM4 Variants with Risk of Multiple Primary Melanomas and Melanoma Survival in Non-Hispanic Whites.
- Adjuvant therapy for stage II melanoma: the need for further studies.
- Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma.
- ASO Author Reflections: The Clinical Relevance of Sentinel Nodes in Minor Lymph Node Fields Such as the Triangular Intermuscular Space in Patients with Melanoma.
- Complex head and neck microsurgery/neurosurgery in Gray platelet syndrome
- Anterolateral thigh, radial forearm and superficial circumflex iliac perforator flaps in oral reconstruction: a comparative analysis.
- Systemic LRG1 expression in melanoma is associated with disease progression and recurrence.
- Comparing Genomic Landscapes of Oral and Cutaneous Squamous Cell Carcinoma of the Head and Neck: Quest for Novel Diagnostic Markers.
- Baseline ultrasound and FDG-PET/CT imaging in Merkel cell carcinoma.
- ASO Visual Abstract: Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma.
- Author Correction: Butler enables rapid cloud-based analysis of thousands of human genomes
- Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?
- The Tumor Immune Microenvironment in Cutaneous Squamous Cell Carcinoma Arising in Organ Transplant Recipients.
- Study protocol for a randomised controlled trial to evaluate the use of melanoma surveillance photography to the Improve early detection of MelanomA in ultra-hiGh and high-risk patiEnts (the IMAGE trial).
- Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
- Time to reconsider the role of sentinel lymph node biopsy in melanoma
- Identification and Characterisation of Infiltrating Immune Cells in Malignant Pleural Mesothelioma Using Spatial Transcriptomics.
- Adjuvant radiotherapy after salvage surgery for melanoma recurrence in a node field following a previous lymph node dissection.
- Measuring the quality of skin cancer management in primary care: A scoping review.
- Human Genetics Society of Australasia Position Statement: Use of Polygenic Scores in Clinical Practice and Population Health. Twin Res Hum Genet.
- Junctional Nevus and Early Melanoma on Sun-Damaged Skin of the Head/Neck: a Clinico-Pathologic Challenge.
- Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort.
- Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.
- Health-related quality of life with nivolumab plus Relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.
- Role of reflectance confocal microscopy for in vivo investigation of oral disorders: White, red and pigmented lesions.
- Uncovering the complex relationship between balding, testosterone and skin cancers in men.
- The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma.
- REPLY to MS#JAAD-D-23-00002R1.
- Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary?
- Spatial mapping reveals granuloma diversity and histopathological superstructure in human tuberculosis.
- IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.
- Lentigo maligna/lentigo maligna melanoma in young patients in Australian tertiary centres.
- Efficacy of ipilimumab 3mn/kg following progression on low-dose ipilimumab in metastatic melanoma.
- Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations.
- Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery.
- MC1R 'r' allele does not increase melanoma risk in MITF E318K carriers.
- Melanotransferrin Functions as a Pro-Oncogenic WNT Agonist: A Yin-Yang Relationship in Melanoma with the WNT Antagonist and Metastasis Suppressor, NDRG1.
- Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.
- Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review
- Clinical features and outcomes of cardiac involvement in patients with cancer treated with immune checkpoint inhibitors.
- Effect of operative time on complications associated with free flap reconstruction of the head and neck
- In vivo reflectance confocal microscopy can detect the invasive component of lentigo maligna melanoma: Prospective analysis and case-control study.
- A sheep in wolf's clothing: Agminated blue naevi masquerading as in-transit melanoma metastases.
- Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey.
- Computer-Aided Diagnosis of Melanoma Subtypes Using Reflectance Confocal Images
- Case series: Immune checkpoint inhibitor-induced transverse myelitis.
- Reply to A. Mangla and E. Hindié.
- Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy.
- Longitudinal trajectory of quality of life for patients with melanoma brain metastases: A secondary analysis from a whole brain radiotherapy randomized clinical trial.
- Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
- Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.
- Plain Language Summary - Development and validation of risk calculators for people with "thin" melanomas on their skin to predict the likelihood that their cancer will return.
- Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
- Author Correction: Pan-cancer analysis of whole genomes
- Lichen sclerosus and immune checkpoint inhibitors: A case and review of the literature.
- Author Correction: The repertoire of mutational signatures in human cancer
- Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.
- IFNγ signaling sensitizes melanoma cells to BH3 Mimetics.
- Author Correction: Patterns of somatic structural variation in human cancer genomes
- Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes.
- Author Correction: Genomic basis for RNA alterations in cancer
- Author Correction: The evolutionary history of 2,658 cancers
- ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
- Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation.
- Association of Germline Variants in Telomere Maintenance Genes (POT1, TERF2IP, ACD, TERT) with Spitzoid Morphology in Familial Melanoma: A Multi-Center Case Series.
- Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma - Authors' reply
- Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.
- Genetics and Genomics of Melanoma: Current Progress and Future Directions.
- Interobserver agreement in the histopathological classification of desmoplastic melanomas
- Neo-Adjuvant Immunotherapy emerges as best medical practice and will be the new standard of care for macroscopic stage III Melanoma.
- Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
- Biology and genetics of acquired and congenital melanocytic naevi
- A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.
- Genomic profiling of metastatic basal cell carcinoma reveals candidate drivers of disease and therapeutic targets.
- Alternatives and Reduced need for Sentinel Lymph Node Biopsy (SLNB) Staging for Melanoma
- Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma
- Representativeness of initial skin biopsies showing pure desmoplastic melanoma: implications for management
- Management of basal cell carcinoma with pulmonary metastasis.
- Neoadjuvant Relatlimab and Nivolumab for Resectable Melanoma.
- Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement
- Interobserver agreement in the histopathological classification of desmoplastic melanomas.
- Hypercalcaemia secondary to hypophysitis and cortisol deficiency: another immunotherapy-related adverse event.
- Views of the Australian public on the delivery of risk-stratified cancer screening in the population: a qualitative study.
- Biology and genetics of acquired and congenital melanocytic naevi.
- Diagnostic biopsies of suspected skin cancer in general practice from 2010 to 2017 in Victoria, Australia
- Embedding electronic patient-reported outcome measures into routine care for patients with stage III MELanoma (ePROMs-MEL): protocol for a prospective, longitudinal, mixed-methods pilot study.
- Perspectives and Experiences of Patient-Led Melanoma Surveillance Using Digital Technologies From Clinicians Involved in the MEL-SELF Pilot Randomized Controlled Trial: Qualitative Interview Study
- Talimogene Laherparepvec in Combination with Immunotherapy, A Viable Option?
- Melanomas in children and adolescents: clinicopathologic features and survival outcomes.
- Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
- Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases.
- Incorporating carbon into health care: adding carbon emissions to health technology assessments.
- Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma.
- Talimogene laherparepvec monotherapy for head and neck melanoma patients.
- Genomic and proteomic findings in early melanoma and opportunities for early diagnosis.
- Reflectance confocal microscopy in Australia: Perspectives on barriers to implementation and uptake.
- Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres.
- The effect of organ-specific tumor microenvironments on response patterns to immunotherapy.
- Informing a position statement on the use of artificial intelligence in dermatology in Australia.
- BRAF inhibitor cessation prior to disease progression in metastatic melanoma: long term outcomes.
- Toripalimab vs High-Dose Interferon-α2b as Adjuvant Therapy for Resected Mucosal Melanoma.
- Which strategies support the effective use of clinical practice guidelines and clinical quality registry data to inform health service delivery? A systematic review.
- Phase 1b Study of Cobimetinib Plus Atezolizumab in Patients with Advanced BRAFV600 Wild-Type Melanoma Progressing on Prior Anti–Programmed Death-1 Therapy.
- Dataset for the Reporting of Merkel Cell Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR).
- Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma.
- ASO Visual Abstract: Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma-An International Multi-institutional Collaboration.
- Tertiary lymphoid structures accompanied by fibrillary matrix morphology impact anti-tumor immunity in basal cell carcinomas.
- Combination of the STING Agonist MIW815 and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-label, Multicenter, Phase Ib Study.
- Discussion of costs and financial burden in clinical practice: A survey of medical oncologists in Australia.
- Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
- Clinical Management of Melanocytic Tumours of Uncertain Malignant Potential (MelTUMPs), including Melanocytomas: A Systematic Review and Meta-Analysis.
- Motivations and Barriers to Participation in a Randomized Trial on Melanoma Genomic Risk: A Mixed-Methods Analysis.
- Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.
- Causes, consequences and clinical significance of aneuploidy across melanoma subtypes.
- Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
- Exploring the Integration of Environmental Impacts in the Cost Analysis of the Pilot MEL-SELF Trial of Patient-Led Melanoma Surveillance.
- Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
- Metastasizing and non-metastasizing thick melanoma: clinicopathological predictors and molecular profiling.
- Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework.
- Causes, consequences and clinical significance of aneuploidy across melanoma subtypes.
- Obesity is associated with altered tumor metabolism in metastatic melanoma.
- Hypoxia controls the glycome signature and galectin-8 - ligand axis to promote pro-tumorigenic properties of metastatic melanoma.
- Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
- Communicating Personal Melanoma Polygenic Risk Information: Participants’ Experiences of Genetic Counseling in a Community-Based Study.
- Validation of self-reported sun exposure against electronic ultraviolet radiation dosimeters.
- Recursive Partitioning to Determine Order of Significance of Regional Metastasis Characteristics in Head and Neck Cutaneous Squamous Cell Carcinoma.
- Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series.
- Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
- Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE).
- Navigating the cellular landscape in tissue: Recent advances in defining the pathogenesis of human disease.
- Comparative genomics provides etiological and biological insights into melanoma subtypes
- Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites.
- Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.
- In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response.
- Views of the Australian public on the delivery of risk-stratified cancer screening in the population: a qualitative study.
- Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting.
- Assessing the value of precision medicine health technologies to detect and manage melanoma.
- Utility of optical coherence tomography in basal cell naevus syndrome: A case report
- Benefit and Toxicity to PD-1 Blockade Varies by Ethnicity in Patients with Advanced Melanoma: An International Multicenter Observational Study
- Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.
- Developing an Australian Melanoma Clinical Outcomes Registry (MelCOR): a protocol paper.
- Survival outcomes of perineural spread in head and neck cutaneous squamous cell carcinoma.
- KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma.
- High-dimensional and spatial analysis reveals immune landscape dependent progression in cutaneous squamous cell carcinoma
- Sentinel node biopsy: linchpin of melanoma management.
- Effect of the SunSafe Training Program on the attitudes, knowledge, and behaviour of Australian high school students towards sun safety: a prospective study
- Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.
- Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.
- Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
- Response to 'Multicentre Selective Lymphadenectomy Trial 1: key primary data remain unavailable.
- Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
- Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome.
- Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.
- Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial.
- Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma.
- Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
- Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022.
- Benchmarking Survival Outcomes Following Surgical Management of pT3 and pT4 Cutaneous Squamous Cell Carcinoma of the Head and Neck.
- Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms.
- Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations.
- Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study.
- Estimating loss in capability wellbeing in the first year of the COVID-19 pandemic: a cross-sectional study of the general adult population in the UK, Australia and the Netherlands.
- Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
- ASO Author Reflections: What Is the Role of Surgery in Management of In-Transit Melanoma in the Modern Era?
- Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.
- Patient-reported outcome measures (PROMs) to guide clinical care: recommendations and challenges.
- Hypofractionated or Conventionally Fractionated Adjuvant Radiotherapy After Regional Lymph Node Dissection for High-Risk Stage III Melanoma.
- Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.
- Protein-based classification of melanoma differentiation subtypes.
- Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.
- MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
- Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected high-risk stage II melanoma in the phase 3 KEYNOTE-716 study.
- Outcomes after definitive treatment for head and neck angiosarcoma.
- The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies.
- Changes in sun protection behaviours, sun exposure and shade availability among adults, children and adolescents in New South Wales, 2003-2016.
- Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma.
- Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue Nevi
- Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events.
- Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow up? Statistical analysis plan for the MEL-SELF randomised controlled trial
- Benchmarking Survival Outcomes Following Surgical Management of pT3 and pT4 Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
- Expression of NGF/proNGF and Their Receptors TrkA, p75NTR and Sortilin in Melanoma
- Treatment of in-transit Merkel cell carcinoma by isolated limb infusion with cytotoxic drugs
- Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
- Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus?
- Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus?
- Multiple eruptive squamoproliferative lesions during anti-PD1 immunotherapy for metastatic melanoma: Pathogenesis, immunohistochemical analysis and treatment
- Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma
- ASO Author Reflections: Surgery for pT3 and pT4 Cutaneous Squamous Cell Carcinomas of the Head and Neck Provides Robust Outcomes Against Which Emerging Treatment Modalities Should be Compared to Determine Their Role in the Standard of Care
- Barriers and facilitators to nurse-led advance care planning and palliative care practice change in primary healthcare: a qualitative study.
- Anatomic position determines oncogenic specificity in melanoma.
- Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling
- Reflectance confocal microscopy - a non-invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma
- Melanoma and Quality of Life
- Anatomic position determines oncogenic specificity in melanoma
- Skin cancer - time for national leadership to meet critical challenges ahead
- Early detection of skin cancer in Australia - current approaches and new opportunities
- Corrigendum to "The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment" [Lung Cancer 165C (2022) 124-132]
- Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes
- Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes.
- Protocol for the implementation of a stepped-care model to address fear of cancer recurrence in patients previously diagnosed with early-stage (0-II) melanoma
- Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre
- Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre.
- Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma
- Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma.
- Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus
- Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
- Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients.
- Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma
- Cost-Effectiveness of PET/CT Surveillance Schedules to Detect Distant Recurrence of Resected Stage III Melanoma
- Dermoscopic features and screening strategies for the detection of small-diameter melanomas
- Sentinel lymph node biopsy rates in Victoria, 2018 and 2019
- Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I)
- Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I).
- Merkel Cell Carcinoma, the Impact of Clinical Excision Margins and Mohs Micrographic Surgery on Recurrence and Survival: A Systematic Review
- The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma
- Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma
- The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma.
- Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
- Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma
- 2021 international consensus statement on optical coherence tomography for basal cell carcinoma: image characteristics, terminology and educational needs
- Barriers and facilitators to nurse-led advance care planning and palliative care practice change in primary healthcare: a qualitative study
- Stage III melanoma: role of lymph node dissection and (neo-)adjuvant systemic therapies
- Isolated limb perfusion for locally advanced melanoma in the immunotherapy era
- ASO Visual Abstract: Talimogene Laherparepvec (T-VEC) for Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: An International Multi-institutional Experience
- Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience
- The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15 mm in thickness)
- Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients
- The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15 mm in thickness).
- Dermatoscopic and clinical features of congenital or congenital-type nail matrix nevi: A multicenter prospective cohort study by the International Dermoscopy Society
- Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy
- Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
- Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).
- International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node Positive Melanoma at Major Referral Centers
- PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence
- An adapter window for precise skin marking during handheld reflectance confocal microscopy scanning
- PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
- The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment
- The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment.
- Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy.
- Patient-reported outcome measures (PROMs) to guide clinical care: recommendations and challenges
- Competing risks analysis with missing cause-of-failure-penalized likelihood estimation of cause-specific Cox models
- Competing risks analysis with missing cause-of-failure-penalized likelihood estimation of cause-specific Cox models.
- Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma
- Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
- Pathology: the next chapter
- Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
- Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells.
- ASO Author Reflections: Validation of Prediction Model for Response to Treatment with T-VEC
- Dermoscopic features and screening strategies for the detection of small-diameter melanomas.
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- Outcome after treatment for sebaceous carcinoma: A multicenter study
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
- Checklist for Evaluation of Image-Based Artificial Intelligence Reports in Dermatology: CLEAR Derm Consensus Guidelines From the International Skin Imaging Collaboration Artificial Intelligence Working Group
- Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial
- Effect of an interactive educational activity using handheld ultraviolet radiation dosimeters on sun protection knowledge among Australian primary school students
- Targeting the neonatal Fc receptor in pemphigus: safety first
- Targeting the neonatal Fc receptor in pemphigus: safety first.
- Pathology: the next chapter.
- BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting
- Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.
- Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis
- Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.
- Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
- BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.
- Microsurgical Scalp Reconstruction: An Overview of the Contemporary Approach
- Gender and immunosuppression impact on Merkel cell carcinoma diagnosis and prognosis. A population based cohort study.
- Merkel cell carcinoma in situ: A systematic review of prognosis and management
- Merkel cell carcinoma in situ: A systematic review of prognosis and management.
- A survey of surgical management of the sentinel node positive melanoma patient in the post-MSLT2 era.
- Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms.
- Postoperative radiotherapy in stage I-III Merkel cell carcinoma
- Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial.
- Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
- External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort
- Adaptive designs for clinical trials have potential advantages, but statistical challenges lurk!
- Multi-trait genetic analysis identifies auto-immune loci associated with cutaneous melanoma.
- PET imaging for cancer immunotherapy: the Immuno-PET
- KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
- Optical coherence tomography features of a tumour of the follicular infundibulum.
- Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside.
- Case report of a challenging medium-sized congenital melanocytic nevus (CMN): Highlighting a role for reflectance confocal microscopy (RCM) for evaluating changing CMN in children.
- Association Between Melanoma Detected During Routine Skin Checks and Mortality.
- Complex melanoma of the scalp: Diagnosis and management aided by confocal microscopy.
- Review BRAF inhibition and the spectrum of granulomatous reactions.
- Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006.
- Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma.
- Acute bilateral phrenic nerve neuropathy causing hypercapnic respiratory associated with checkpoint inhibitor immunotherapy.
- Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis.
- High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy
- Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.
- Interventions to Increase Sunscreen Use in Adults: A Review of the Literature.
- Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
- Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
- Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas
- Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.
- Irregular Sleep/Wake Patterns Are Associated With Reduced Quality of Life in Post-treatment Cancer Patients: A Study Across Three Cancer Cohorts
- A practical guide on the use of Imiquimod cream for Lentigo Maligna.
- Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
- Immune checkpoint inhibitors in melanoma
- Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews.
- PARP Inhibitors in Melanoma-An Expanding Therapeutic Option?
- Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts.
- Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition.
- Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas.
- Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis.
- Cutaneous clear cell sarcoma with an epidermal component mimicking melanoma.
- Strengthening melanoma prevention and early detection among people with type 2 diabetes.
- A survey of surgical management of the sentinel node positive melanoma patient in the post-MSLT2 era.
- Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
- TMB and Inflammatory Gene Expression Associated With Clinical Outcomes Following Immunotherapy in Advanced Melanoma
- TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
- Residual melanoma in wide local excision specimens after 'complete' excision of primary cutaneous in situ and invasive melanomas.
- Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial
- The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients
- Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy
- Survival Outcomes of Salvage Metastasectomy after Failure of Modern-Era Systemic Therapy for Melanoma
- ASO Author Reflections: Surgical Resection May Improve the Outcome for Patients with Residual Metastatic Melanoma When Modern Systemic Therapies Have Not Achieved Complete Disease Control
- In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?
- Confocal microscopy, dermoscopy, and histopathology features of atypical intraepidermal melanocytic proliferations associated with evolution to melanoma in situ
- Correction to: Histological regression in melanoma: impact on sentinel lymph node status and survival.
- Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma
- Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply
- Surveillance of patients with thin melanoma.
- Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy.
- Deep Learning for Basal Cell Carcinoma Detection for Reflectance Confocal Microscopy.
- Histological regression in melanoma: impact on sentinel lymph node status and survival.
- Knowledge, views and expectations for cancer polygenic risk testing in clinical practice: a cross-sectional survey of health professionals.
- Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.
- Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.
- Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations.
- A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences.
- Characterizing the Clinical Implications of Histologic Regression in Melanoma Requires Clear Diagnostic Criteria That Are Consistently Applied-Reply.
- Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets.
- Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy.
- Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location.
- Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers.
- Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage III melanoma.
- Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies.
- Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
- PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.
- Identifying the 'Active Ingredients' of an Effective Psychological Intervention to Reduce Fear of Cancer Recurrence: A Process Evaluation.
- Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma.
- Neoadjuvant Immunotherapy in Melanoma – The New Frontier
- Neoadjuvant immunotherapy in melanoma - the new frontier
- Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi
- Counting mitoses: SI(ze) matters!
- Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis.
- Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity.
- Current Challenges in Access to Melanoma Care: A Multidisciplinary Perspective.
- Validation of the American Joint Committee on Cancer Staging in Squamous Cell Carcinoma of the Vermilion Lip
- Treatment of in-transit melanoma metastases using intralesional PV-10
- Immunotherapy in advanced Merkel cell carcinoma: Sydney west cancer network experience.
- Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data.
- Melanoma Cell State-Specific Responses to TNFα
- Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial.
- Lentigo maligna: defining margins and predictors of recurrence utilising clinical, dermoscopic, confocal microscopy and histopathology features
- Acceptability of risk-stratified population screening across cancer types: Qualitative interviews with the Australian public.
- Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
- Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis
- The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
- Flat scalp melanoma dermoscopic and reflectance confocal microscopy features correspond to histopathologic type and lesion location.
- Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
- The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics.
- An independent external validation of melanoma risk prediction models using the Australian Melanoma Family Study.
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
- Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
- Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families
- Publication metrics: it really is all about the numbers
- Not all melanomas are created equal: A review and call for more research into nodular melanoma
- Diagnostic tools used for melanoma: A survey of Australian general practitioners and dermatologists
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy trial II (MSLT-2)
- Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging: Results From a Large Multicenter Trial.
- The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials.
- Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
- A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma.
- Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.
- Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners.
- Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners.
- Immunotherapy use outside clinical trial populations: never say never?
- Novel adjuvant options for cutaneous melanoma.
- Oral Manifestations in Melanoma Patients Treated with Target or Immunomodulatory Therapies.
- Recent advancements in melanoma management.
- Treatment of in-transit melanoma metastases using intralesional PV-10.
- Longitudinal melanonychia striata mimicking a melanoma during pregnancy.
- The worse survival outcomes reported for melanoma patients having sentinel node biopsy after lymphoscintigraphy the previous day do not appear to be due to overnight migration of Tc99m-nanocolloid tracer.
- Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.
- Targeting NK Cells to Enhance Melanoma Response to Immunotherapies.
- Feasibility of modifying the hospital environment to reduce the length of amnesia after traumatic brain injury: a pilot randomized controlled trial.
- Validated specialty-specific models for multi-disciplinary microsurgery training laboratories: a systematic review.
- Organ transplantation and outcomes in patients with a past history of melanoma: A systemati.c review and meta-analysis
- Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.
- Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
- Hematological immune related adverse events after treatment with immune checkpoint inhibitors.
- γδ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival.
- Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling.
- To be mortal is human: professional consensus around the need for more psychology in palliative care.
- Surgical excision margins in primary cutaneous melanoma: A systematic review and meta-analysis
- Surgical excision margins in primary cutaneous melanoma: A systematic review and meta-analysis.
- Predicting sentinel node positivity in patients with melanoma: external validation of a risk-prediction calculator (the Melanoma Institute Australia nomogram) using a large European population-based patient cohort.
- Efficiency of Detecting New Primary Melanoma Among Individuals Treated in a High-risk Clinic for Skin Surveillance.
- Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region.
- Estimating the potential impact of interventions to reduce over-calling and under-calling of melanoma.
- The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials.
- Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas.
- Tumour gene expression signature in primary melanoma predicts long-term outcomes.
- School-based interventions to improve sun-safe knowledge, attitudes and behaviors in childhood and adolescence: A systematic review.
- Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
- Implementation of patient-reported outcome measures and patient-reported experience measures in melanoma clinical quality registries: a systematic review.
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
- Targeting the Microbiome to Overcome Resistance.
- Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines.
- Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
- Differences in Melanoma Between Canada and New South Wales, Australia: A Population-Based Genes, Environment, and Melanoma (GEM) Study.
- Sex bias of females in survival from cancer and infections. Is X the answer?
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Venues
- McCormick Place Convention Center
- San Diego Convention Center
- JW Marriott Los Angeles
- O2 Universum
- Colorado Convention Center
- Virtual Event
- Peppers Silo Hotel
- Sydney Showground
- Frankston Pier
- Bong Bong St, Borwal
- Victory Lounge, Optus Stadium
- Colley Terrace
- Miller Street, North Sydney
- St Lukes Wellness Hub
- Mornington Park
- Pullman Melbourne on the Park
- St Vincent’s Private Community Hospital Griffith
- The Education Centre at St Vincent's Hospital Lismore
- Apex Park, Lake Albert
- The Strand
- Ashburner St & South Steyne
- Batman Avenue
- Buhk Family Park
- Hanging Rock
- Grand Slam Oval
- Cottesloe Beach
- Noosa Parade, Noosa Heads
- Translational Research Institute
- Xavier Catholic College
- St Michael's Collegiate School, Senior School Campus
- Main Beach
- Kerry Packer Education Centre
- French Fields
- Margaret Street, Brisbane City
- Fogarty Park, Cairns
- Macquarie Street, Sydney
- John Dunmore Lang Place
- PW1 Castray Esplanade
- The Tan
- Princes Park
- Melbourne Zoo
- The University Club of Western Australia
- Queen Elizabeth Park
- Champion Lakes Regatta Centre
- Perth Convention and Exhibition Centre
- ICC Sydney and Cockle Bay - Darling Harbour
- C3 Convention Centre
- Subiaco Football Club
- Crowne Plaza (Aura Event Space - Level 12)
- Notre Dame University (Wagga Wagga Clinical School)
- Hyatt Regency
- Civic Theatre Wagga Wagga
- French Fields
- Margate Tavern
- Boathouse Centre
- 3six5 - Event Space
- Brighton Football Club
- Harry Perkins Institute of Medical Research (North)
- Online via Zoom
- Perth
- Rivershed
- University of Sydney
- The Poche Centre
- Wagga Wagga Country Club
- Balmoral Beach Club
- RACV Royal Pines Resort
- Cancer Wellness Centre
- The Royal Yacht Club of Tasmania
- The University of Notre Dame Lecture Theatre
- Skipper Lane Car Park
- Spreyton Football Club
- Riverina Day Surgery
- Coolangatta
- Bradfield Park
- Noosa Heads, Noosaville
- Subiaco Football Club
- The Boatshed
- National
- Or watch online.
- The Poche Centre (or via Zoom)
- The Range Function Centre
Organisers
Events
Portfolio
Academic Authors
- Long, Georgina
- van Akkooi, Alexander
- Carlino, Matteo
- Ch'ng, Sydney
- Cust, Anne
- Coker, David
- Colebatch, Andrew
- Ferguson, Peter
- Guitera, Pascale
- Hersey, Peter
- Hong, Angela
- Kefford, Rick
- Lo, Serigne
- Mann, Graham
- Martin, Linda
- Menzies, Alex
- Morton, Rachael
- Nieweg, Omgo
- Pires da Silva, Ines
- Pennington, Tom
- Rawson, Robert
- Rizos, Helen
- Rtshiladze, Michael
- Saw, Robyn
- Scolyer, Richard
- Shannon, Kerwin
- Spillane, Andrew
- Stretch, Jonathan
- Thompson, John
- Varey, Alex
- Wilmott, James
Organiser Categories
Page load link
